Biosplice Therapeutics
Biosplice Therapeutics: Pioneering tissue regeneration and degenerative disease solutions via Wnt pathway modulation.
Founded
2008Biosplice Therapeutics: Pioneering tissue regeneration and degenerative disease solutions via Wnt pathway modulation.
Founded in San Diego, Biosplice Therapeutics focuses on pioneering tissue regeneration and solutions for degenerative diseases through Wnt pathway modulation. Their core mission is to restore health by delivering first-in-class therapies that harness alternative splicing, addressing unmet medical needs in regenerative medicine and oncology. The company develops therapeutics aimed at conditions like osteoarthritis, where no drugs currently arrest disease progression, and seeks to overcome the diversity and adaptability of lethal cancers.
Biosplice Therapeutics has garnered attention for its innovative approach and significant potential impact on medical treatments. Notable affiliated individuals include key researchers and scientists specializing in molecular biology and regenerative medicine. The company has achieved milestones in preclinical and clinical trials, demonstrating promising results in tissue regeneration and cancer therapy. Their work has the potential to revolutionize treatment paradigms, offering hope to millions of patients suffering from currently untreatable conditions.
Companies similar to Biosplice Therapeutics include Surrozen, Blade Therapeutics, Spinogenix and Amplicore.
Biosplice Therapeutics was founded in 2008.
Biosplice Therapeutics' headquarters is located in San Diego, CA, US.
Biosplice Therapeutics' most recent funding round was for $120M (USD) in April 2021.
As of Apr 15, 2021, Biosplice Therapeutics has disclosed funding of $778M (USD). Undisclosed round amounts are excluded.
Biosplice Therapeutics has 63 employees as of Feb 5, 2024.
Amplicore
